Trim 20% of GILD position over 3-5 sessions, front-loaded ahead of FOMC; maintain residual 80% for dividend carry with $142.34 stop and tighter re-engagement criteria.
Trim 20% of GILD position (top of validated 15-20% band, justified by elevated severity: confirmed distribution on tape, balance sheet impairment in Q2 2026 financials, MACD fresh bearish cross, and 3 binary catalysts in 60-day window) over 3-5 trading sessions, front-loaded ahead of tomorrow's FOMC, selling into $147-150 bid zone or accepting $146-level exits if Fed hits first. Maintain residual 80% for dividend carry (2.24% yield, 2.4x FCF coverage); defend $142.34 daily close as thesis-invalidating stop. Re-engage on 10 EMA reclaim ($145.50) plus MACD positive within 3 sessions, OR close above $147.52 with MACD positive—do not wait for $151+ repair. Destination: cash and T-bills only. Rating is Underweight (trim, not exit) per 8/10/8/18 lessons validating full exits from FCF-positive defensives destroy alpha; GILD's HIV moat (10% YoY growth), Yeztugo ramp (>$1B at >70% persistence), $9.77B TTM FCF, and 0.35-beta floor justify preserving core through Q3 print.
| Position | Action |
|---|---|
| Current setup (confirmed distribution, balance sheet impairment, MACD bearish cross, 3 binary catalysts in 60 days) | Trim 20% of position (top of validated 15-20% trim band, below destruction threshold of 20-25%) |
| Post-trim residual | Maintain 80% residual for 2.24% dividend yield with 2.4x FCF coverage; monitor for quarterly FCF materially below $2B run-rate |
| Trimmed capital destination | Cash and short-duration Treasuries only; no rotation into new names |
| FOMC timing risk | Front-load execution over 3-5 sessions; accept $146-level exits if 147-150 zone doesn't materialize before Fed |
| Prior 30-40%, 35-40%, or 50% trim proposals | Reject as overcalibrated and entering destruction territory per 9/11 reflection |
GILD at $146 represents a classic post-rally consolidation in a long-term uptrend, offering an attractive entry point backed by strong FCF generation, defensive characteristics in a hawkish macro environment, and multiple upcoming catalysts from new HIV product launches and pipeline expansion.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | 134.02 | bullish |
| close_50_sma | 138.73 | bullish |
| close_10_ema | 146.40 | neutral |
| rsi | 55.49 | neutral |
| macd | 2.24 | bearish |
| macd_signal | 3.09 | bearish |
| macd_histogram | -0.85 | bearish |
| bollinger_middle | 147.02 | neutral |
| bollinger_upper | 151.70 | neutral |
| bollinger_lower | 142.34 | bullish |
| atr_14 | 3.47 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
The TTM EPS loss of -$2.65 is a GAAP accounting artifact from a strategic $11.21B acquisition, not operational deterioration
↩ rebuts: “Bear's use of headline EPS as a fundamental red flag”
EV: +13-16.4% (target $165-170 over 6-9 months from $146) · concedes: Net debt jumped $5.7B in six months to $23B with Debt/Equity at 223% looks stretched on the surface; Biktarvy faces a patent cliff post-2030 - though management is building the next Biktarvy with lenacapavir-based combinations; Should not chase - this is an entry point, not a momentum play
GILD's "inflection point" is actually a Wyckoff-style distribution event where institutional investors are selling into retail dip-buyers, with deteriorating balance sheet metrics, unproven HIV franchise extensions, and macro headwinds making the risk/reward asymmetric to the downside at current levels.
EV: -20% to -25% (realistic bear scenario with acquisition write-down + macro shock + multiple compression) · concedes: 5-year +146% appreciation has likely already priced in significant bullish narrative; 3 catalysts in 60 days (FOMC, Q3 earnings, commercial uptake data) are also 3 binary risks — acknowledged but still viewed as asymmetric downside; MACD cross and distribution volume are early warnings, not confirmed breakdowns yet — discipline is to exit rather than hold blindly; Long-term trend and dividend support suggest HOLD with bearish bias rather than panic selling
→ vs conservative: 200 SMA is a lagging indicator showing where stock has been, not where it's going; waiting for VWMA reclaim at $147.28 or 50 SMA test at $138.73 means buying into already-deteriorating technicals
→ vs neutral: Good news gets faded during distribution; HIV franchise story and pipeline messaging were "on tape at $148 two weeks ago" yet stock sold off anyway; defensive bid thesis is a macro argument, not a stock argument for a name with actively deteriorating technicals and post-acquisition balance sheet impairment
| neutral |
| vwma | 147.28 | neutral |
Support: 138.73 · 142.34 · 142.94 · 143.72 · 144 | Resistance: 146.4 · 147.02 · 147.28 · 151.22 · 151.7
GILD is in a corrective phase within a longer-term uptrend, with price 5.4% above the 50 SMA and 9.2% above the 200 SMA. Short-term momentum has turned bearish following a MACD bearish crossover, with the histogram in negative territory for the first time since early August. RSI at 55.49 is neutral, Bollinger Bands show price near the lower band at $142.34, and ATR at $3.47 indicates moderate volatility. Volume analysis reveals heavier selling on Sep 8 and 10 versus lighter volume on the recent bounce, suggesting the recovery is tentative. The bias is neutral-to-cautiously-bullish; existing longs should hold with a trailing stop at the Sep 11 low of $143.72, while new buyers should wait for either a VWMA reclaim above $147.28 or a successful tag-and-bounce of the 50 SMA at $138.73.
Market Cap
$181.4 B
52-Week High
$157.29
52-Week Low
$108.46
50-Day Moving Average
$138.39
200-Day Moving Average
$134.84
Beta
0.35
Dividend Yield
2.24%
Forward P/E
14.79x
P/B Ratio
15.35x
PEG Ratio
2.14
FCF Yield
~5.4%
Revenue TTM
$30.46 B
Q2 2026 Revenue
$7.803 B
Gross Margin
~80%
Operating Margin TTM
~33.7%
Q2 2026 Operating Income
$2.539 B
Q2 2026 Normalized EBITDA
$3.281 B
Return on Assets
14.1%
TTM Net Income
-$3.24 B
TTM EPS
-$2.65
Q2 2026 EPS
-$8.45
Forward EPS
$9.89
Profit Margin TTM
-10.6%
Total Assets
$49.36 B
Cash & Equivalents
$3.18 B
Total Debt
$26.25 B
Net Debt
$23.07 B
Stockholders' Equity
$11.83 B
Goodwill
$8.31 B
Other Intangibles
$14.03 B
Working Capital
$2.93 B
Current Ratio
1.27x
Debt/Equity
223%
Tangible Book Value
-$10.52 B
Interest Coverage
~10x
TTM Operating Cash Flow
~$13.6 B
TTM Free Cash Flow
$9.77 B
TTM CapEx
~$0.63 B
Annual Dividend
~$4.0 B
Quarterly Dividend
~$1.03 B
TTM Dividends Paid
~$4.07 B
TTM Share Repurchases
~$1.98 B
Dividend Coverage FCF
~2.4x
Q2 2026 Acquisition
$11.21 B
Q2 2026 Special Charges
-$12.93 B
Q2 2026 IPR&D Write-off
-$12.59 B
Q4 2025 Normalized EBITDA
$4.27 B
Strengths
Concerns
Gilead presents a complex fundamental picture: Q2 2026 GAAP results were severely distorted by $12.93B in one-time acquisition and IPR&D write-off charges, producing a -$8.45 EPS loss that masks robust underlying operational performance with ~$10B annual FCF, 33.7% operating margins, and 14.1% ROA. The $11.21B Q2 2026 acquisition drove a significant balance sheet deterioration (Debt/Equity jumped from 110% to 223%, net debt up $5.7B), but cash flow generation (~10x interest coverage, ~2.4x dividend coverage) remains more than adequate to service obligations. With forward EPS of $9.89 and the stock trading at 14.79x forward P/E with a 2.24% dividend yield, Gilead offers attractive valuation and income for risk-averse investors seeking defensive healthcare exposure, though the negative tangible book value and acquisition integration risks warrant monitoring.
Macro: Risk-off macro environment with 10Y Treasury at highest level since 2007; Fed pricing no rate cuts in 2026 at 94% probability; US recession 2026 at 16% (rising); oil above $100/bbl adding inflation pressure; equity indices declining into FOMC decision day. Defensive sectors (utilities, large-cap pharma, consumer staples) are relatively bid in this environment.